Efficacy of BCG in bladder cancer may be predicted by cytokine response

August 1, 2010

Bacillus Calmette-Guérin (has been the standard of care for bladder cancer for nearly 40 years. Little is known about BCG or its mechanism of action, however. A trial currently under way at M.D. Anderson Cancer Center, Houston, may help urologists to separate responders from nonresponders early and tailor therapy for optimal results in those who respond to the drug.